Clinical Trials of Oncolytic Viruses in Breast Cancer

Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach. There are three different types of oncolytic viruses used in clinical trials; (i) oncolytic viruses with natural anti-neoplastic properties; (ii) oncolytic viruses designed for...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 803050
Main Authors Carter, Mary E, Koch, André, Lauer, Ulrich M, Hartkopf, Andreas D
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.12.2021
Subjects
breast cancer
clinical trials
Oncology
oncolytic virus
review
virotherapy
breast cancer
clinical trials
virotherapy
oncolytic virus
review
Online AccessGet full text

Cover

More Information
Summary:Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach. There are three different types of oncolytic viruses used in clinical trials; (i) oncolytic viruses with natural anti-neoplastic properties; (ii) oncolytic viruses designed for tumor-selective replication; (iii) oncolytic viruses modified to activate the immune system. Currently, fourteen different oncolytic viruses have been investigated in eighteen published clinical trials. These trials demonstrate that oncolytic viruses are well tolerated and safe for use in patients and display clinical activity. However, these trials mainly studied a small number of patients with different advanced tumors including some with breast cancer. Future trials should focus on breast cancer and investigate optimal routes of administration, occurrence of neutralizing antibodies, viral gene expression, combinations with other antineoplastic therapies, and identify subtypes that are particularly suitable for oncolytic virotherapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Breast Cancer, a section of the journal Frontiers in Oncology
Reviewed by: Masmudur Mohammed Rahman, Arizona State University, United States; Konstantin Kousoulas, Louisiana State University, United States; Robert Kratzke, University of Minnesota Twin Cities, United States
Edited by: Assia Konsoulova, Complex Oncological Center (Burgas), Bulgaria
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.803050